EMA updates Questions and Answers Document
![Drug Master File Procedures in the EU, the US and Japan - Live Online Training](files/eca/userImages/training.img/Z-ECA-Drug-Master-File-Procedures-LOT.jpg)
Recommendation
17/18 September 2024
With updates on the CEP 2.0!
The European Medicines Agency (EMA) provides answers to frequently asked questions on Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) on its website. These have been compiled and agreed by the GMP/GDP Inspectors Working Group.
This Q&A guidance provides additional interpretation of the European Union (EU) GMP Guidelines and GDP Guidelines published by the European Commission. The list is regularly supplemented or updated. Currently, the legal requirements for veterinary medicinal products have been newly regulated in the EU. To this end, the previously applicable Directive 2001/82/EC - EU Codex for Veterinary Medicinal Products will be repealed on 28 January 2022 and replaced by Regulation (EU) 2019/6. This regulation includes provisions on authorisation, post-authorisation measures, manufacture, import, export, supply and use of veterinary medicinal products, as well as restrictions and sanctions. Accordingly, the questions and answers have now been updated.
The new chapter deals with requirements for active substances that are used as starting materials for the manufacture of veterinary medicinal products. The following questions, among others, are answered:
- Do active substances used as starting materials in veterinary medicinal products have to comply with the same GMP requirements for active substances (for human medicinal products)?
- Are there new obligations regarding active substances for the manufacture of veterinary medicinal products?
- Is a GMP certificate mandatory and how is it issued?
- What applies in the case of inspections?
Related GMP News
26.06.202410 points on how the FDA's CDER monitors the Quality of Medicinal Products
08.05.2024EMA Plans for the next three Years
30.04.2024Lean GMP: is "right-sizing" GMP and Compliance possible?
24.04.2024Unexpected Deviations: the Role of the QP
10.04.2024FDA's current Thinking on KPIs and Quality Metrics
21.02.2024What is the African Medicines Agency?